Article Text
Articles
Anticoagulation with ▼dabigatran or▼rivaroxaban
Relevant BNF section: 2.8.2
Abstract
Anticoagulants such as low molecular weight heparins (LMWH; e.g. enoxaparin) and ▼fondaparinux are cost-effective measures for reducing the likelihood of venous thromboembolism (VTE) in patients undergoing surgery.1 ▼Dabigatran etexilate (Pradaxa-Boehringer Ingelheim)2 and ▼rivaroxaban (Xarelto – Bayer) are fixed-dose oral anticoagulants licensed in the European Union (EU) for the prevention of VTE in adults who have undergone or are undergoing elective replacement of the hip or knee joints.2,3 Here, we consider their place for these indications.
Statistics from Altmetric.com
Relevant BNF section: 2.8.2
Footnotes
↵* For an explanation of non-inferiority trials, see DTB 2008; 46: 55–6.